Temple surgeon working to bring new stent for aortic aneurysms to patients in the US

(Press-News.org) Contact information: Jeremy Walter
Jeremy.Walter@tuhs.temple.edu
267-838-0398
Temple University Health System
Temple surgeon working to bring new stent for aortic aneurysms to patients in the US Temple University Hospital (TUH) could be among the first U.S.-based hospitals to test a new device known as a multilayer stent in patients suffering from aortic aneurysm, a condition characterized by the formation of a potentially life-threatening bulge in the aorta. Approved in Europe in 2010, the device has already been used to help hundreds of European patients with the condition, and Grayson H. Wheatley III, MD, FACS, Associate Professor of Surgery at Temple University School of Medicine, and Director of Aortic & Endovascular Surgery at TUH, thinks thousands more could benefit in the United States.

Dr. Wheatley, a leading expert on multilayer stent technology, spoke about the device at the 50th annual meeting of the Society of Thoracic Surgeons (STS), held January 25-29, in Orlando, Florida. "Most U.S. physicians don't know about [the multilayer stent]," he said. But if approved in the United States, it could bring important changes to the treatment of aortic aneurysm for American patients, some 10,000 of whom die from the disease each year.

Multilayer stents incorporate key advantages over traditional aortic stents -- among the most important of which is the elimination of the need for surgical bypass grafts. Unlike traditional fabric-covered stents, multilayer stents have no fabric covering and are composed of an intricately-layered metal-mesh framework that -- by virtue of its unique, three-dimensional geometric design -- affects the flow of the blood such that even when the placement of the stent covers the openings to branching vessels to the brain or abdomen, the blood can flow unhindered into those arterial branches. As a result, the need to perform open-heart procedures to create bypasses has been eliminated.

"The fluid dynamics of the uniquely-constructed multilayer stent allows it to stay open to the branches, but also clot off the aneurysm, and represents a novel method to treat aortic aneurysms," said Dr. Wheatley.

"The multilayer stent changes the dynamic properties of blood as blood flows through the metal frame of the stent," continued Dr. Wheatley. Those changes include less turbulent and more directed blood flow through the aneurysm and branching vessels when the stent is in place. The altered dynamic properties in turn reduce the amount of pressure exerted by the blood on the aneurysm, which allows the aneurysm to clot and heal itself.

The idea to test a stent designed without a fabric covering originated with engineers in Belgium who specialize in the study of blood flow. Dr. Wheatley and his primary collaborator, surgeon and founder of the Arizona Heart Institute Edward Diethrich, MD, tested the device in pre-clinical trials in the early 2000s. The Belgium-based medical technology company Cardiatis then developed the multilayer stent for clinical use.

Dr. Diethrich, working at the Arizona Heart Foundation, is now encouraging the multilayer stent's approval by the U.S. Food and Drug Administration. Supporting that effort is Dr. Wheatley's continued research into multilayer stent technology. In recent collaborations with physicians in France where the stent is approved for use, as well as a review of published global outcomes, Dr. Wheatley found that patients who had received multilayer stents experienced outcomes that were similar to or better than those of patients who had received traditional stents.

He also found that patients with multilayer stents recovered more quickly. The improved recovery rate can be attributed to the fact the multilayer stents are, as yet, the most minimally invasive technology developed for aortic aneurysms. "Patients who are not candidates for open surgery or standard aortic stent-grafts could be candidates for a multilayer stent," Dr. Wheatley said.

Even with the approval of multilayer stents, however, under-screening remains a major obstacle to reducing annual deaths from aortic aneurysm in the United States. The Screening Abdominal Aortic Aneurysms Very Efficiently (SAAAVE) Act, which was passed in 2006, made ultrasound screening for abdominal aortic aneurysms a part of the routine initial physical exam given when persons age 65 join Medicare. The act represented a significant improvement, but more programs like SAAAVE are needed, according to Dr. Wheatley.

Dr. Wheatley delivered his presentation on multilayer stent technology at the STS meeting on January 26th.

### Editor's Note: Neither Dr. Grayson Wheatley nor members of his immediate family have any financial interest in Cardiatis.

About Temple Health Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System and by Temple University School of Medicine. Temple University Health System (TUHS) is a $1.4 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH), ranked among the "Best Hospitals" in the region by U.S. News & World Report; TUH-Episcopal Campus; TUH-Northeastern Campus; Fox Chase Cancer Center, an NCI-designated comprehensive cancer center; Jeanes Hospital, a community-based hospital offering medical, surgical and emergency services; Temple Transport Team, a ground and air-ambulance company; and Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices. TUHS is affiliated with Temple University School of Medicine. Temple University School of Medicine (TUSM), established in 1901, is one of the nation's leading medical schools. Each year, the School of Medicine educates approximately 840 medical students and 140 graduate students. Based on its level of funding from the National Institutes of Health, Temple University School of Medicine is the second-highest ranked medical school in Philadelphia and the third-highest in the Commonwealth of Pennsylvania. According to U.S. News & World Report, TUSM is among the top 10 most applied-to medical schools in the nation.